Led by Daniel Harki, Ph.D., and Kaylee Schwertfeger, Ph.D., the Cellular Mechanisms of Cancer program brings together some 65 researchers from the Masonic Cancer Center who are focused on the cellular aspects of malignant cancer progression.
With Masonic support, the group has continued to lead impactful research over the last year with the overarching goal of translating discoveries into novel cancer therapies. Examples of their recent studies focus on everything from identifying potential new cellular culprits in breast cancer, to overcoming resistance to prostate cancer therapy. Masonic funding has also helped the group leverage larger new awards for their research from the NIH and other national organizations.
The Cellular Mechanisms program places high priority on mentoring talented junior faculty. Program leaders meet with new group members throughout the year, and new members present their work in program meetings. Additionally, the program links members to opportunities to participate in the University’s Epigenetics Consortium and the Masonic Cancer Center’s Translational Working Groups.